secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001140361-25-035337
Event type: other
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics receives sixth U.S. patent for GTx-104 dosing regimen; protection extended to 2043
--------------------------------------------------------------------------------

- US Patent 12,414,943 issued for I.V. nimodipine dosing regimen used in Phase 3 STRIVE-ON trial.
- First method-of-use patent for GTx-104; adds to five composition patents expiring 2037.
- Patent protection for GTx-104 extended to 2043.
- GTx-104 is a clinical-stage injectable nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).
- Orphan Drug Designation provides 7 years of marketing exclusivity upon FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125035337/0001140361-25-035337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125035337/ef20055717_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-035337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer